Key Factors and Emerging Trends Shaping the House Dust Mite Allergy Market Landscape

The house dust mite allergy market is positioned for significant expansion over the coming years, driven by advances in treatment options and growing awareness around allergy management. This sector is evolving steadily as personalized therapies and preventive care become more widely adopted, paving the way for broader market growth and new opportunities.

Projected Growth Trajectory of the House Dust Mite Allergy Market
The size of the house dust mite allergy market is anticipated to reach $4.62 billion by 2030, growing at a strong compound annual growth rate (CAGR) of 14.3%. Key factors contributing to this surge include the increased use of personalized immunotherapy, a heightened focus on proactive allergy prevention, growth in home-based allergy treatments, and a demand for sustained symptom relief. Additionally, breakthroughs in biologic therapies for allergies are expected to accelerate market expansion. Prominent trends shaping the market encompass the rising uptake of immunotherapy treatments, especially sublingual allergy tablets, wider adoption of early diagnostic testing, and a growing emphasis on tailored allergy care.

Download a free sample of the house dust mite allergy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9304&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Leading Companies Driving Innovation in the House Dust Mite Allergy Market
Several major players dominate the house dust mite allergy landscape, including Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, and GlaxoSmithKline.
In a notable development, Stallergenes Greer, a France-based biopharmaceutical firm specializing in allergen immunotherapy, partnered with China-based Nuance Pharma in September 2025. This collaboration aims to broaden the distribution of Stallergenes Greer's sublingual immunotherapy tablet, Actair, across China. The partnership seeks to enhance patient access to scientifically backed allergy treatments and extend the availability of effective immunotherapy options for those suffering from house dust mite-induced allergic rhinitis.

Emerging Focus on Innovative Treatment Approaches
Industry leaders are increasingly investing in cutting-edge solutions to combat the rising incidence of house dust mite allergies. One such advancement is the development of sublingual tablets, which are placed under the tongue to deliver controlled doses of the allergen and help build tolerance over time.
For example, in January 2023, ALK-Abelló A/S, a pharmaceutical company based in Denmark, received FDA approval for ODACTRA-a sublingual tablet targeting adolescents aged 12 to 17 with house dust mite allergies. This approval extends the tablet's existing indication for adults and addresses a significant gap, as nearly half of all allergy sufferers are sensitive to house dust mites. Clinical trials affirmed that ODACTRA effectively reduces allergy symptoms with a safety profile comparable to adults, although patients are advised to keep auto-injectable epinephrine available due to a rare risk of severe allergic reactions.

View the full house dust mite allergy market report:
https://www.thebusinessresearchcompany.com/report/house-dust-mite-allergy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Dominant Market Segments in House Dust Mite Allergy Treatments
The house dust mite allergy market is categorized into several key segments:
1) Product Type: Tablets, Nasal Drops, Injectable
2) Diagnostic Methods: Skin Prick Test (SPT), Specific Immunoglobulin E (IgE) Blood Test, Other Diagnosis
3) Dosage Forms: Solid, Liquid
4) End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Further sub-segmentation includes tablets split into sublingual and oral forms; nasal drops differentiated as antihistamine or corticosteroid types; and injectable treatments divided between allergen immunotherapy injections and corticosteroid injections.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.